These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35432693)

  • 1. Omicron: the highly mutational COVID-19 variant with immune escape.
    Khajotia R
    Pan Afr Med J; 2022; 41():84. PubMed ID: 35432693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.
    Kannan S; Shaik Syed Ali P; Sheeza A
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):8019-8022. PubMed ID: 34982466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants.
    Özüdoğru O; Bahçe YG; Acer Ö
    Ir J Med Sci; 2023 Apr; 192(2):751-756. PubMed ID: 35711013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
    Saxena SK; Kumar S; Ansari S; Paweska JT; Maurya VK; Tripathi AK; Abdel-Moneim AS
    J Med Virol; 2022 Apr; 94(4):1738-1744. PubMed ID: 34905235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity.
    Mohsin M; Mahmud S
    Medicine (Baltimore); 2022 May; 101(19):e29165. PubMed ID: 35583528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.
    Zhang L; Li Q; Liang Z; Li T; Liu S; Cui Q; Nie J; Wu Q; Qu X; Huang W; Wang Y
    Emerg Microbes Infect; 2022 Dec; 11(1):1-5. PubMed ID: 34890524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immediate reinfection with Omicron variant after clearance of a previous SARS-CoV-2 infection.
    Mencacci A; Gili A; Camilloni B; Bicchieraro G; Spaccapelo R; Bietta C; Stracci F
    J Infect Public Health; 2022 Sep; 15(9):983-985. PubMed ID: 35963101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.
    CDC COVID-19 Response Team
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(50):1731-1734. PubMed ID: 34914670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa.
    Wang L; Cheng G
    J Med Virol; 2022 Apr; 94(4):1728-1733. PubMed ID: 34897752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-COV-2 Variants: Differences and Potential of Immune Evasion.
    Hirabara SM; Serdan TDA; Gorjao R; Masi LN; Pithon-Curi TC; Covas DT; Curi R; Durigon EL
    Front Cell Infect Microbiol; 2021; 11():781429. PubMed ID: 35118007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa.
    Yu Y; Yu Y; Zhao S; He D
    Math Biosci Eng; 2022 Jul; 19(10):10361-10373. PubMed ID: 36031998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune evasion ability of Delta variant is comparable to that of Beta variant in South Africa.
    He D; Chen B; Zhao S; Stone L
    BMC Public Health; 2023 Mar; 23(1):511. PubMed ID: 36927400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress in research of 2019-nCoV Omicron variant].
    Huang Y; Li YH; Xie SL; Rong ZH; Li BS; Kang M; Deng AP; Li Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 May; 43(5):655-662. PubMed ID: 35589568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera.
    Zhou W; He P; Li J; Liu H; Shi M; Yu J; Wei H
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in the infection fatality rate of Omicron variant compared with previous variants in South Africa.
    Liu Y; Yu Y; Zhao Y; He D
    Int J Infect Dis; 2022 Jul; 120():146-149. PubMed ID: 35462038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain.
    Ye G; Liu B; Li F
    Nat Commun; 2022 Mar; 13(1):1214. PubMed ID: 35241675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Omicron variant (B.1.1.529): A concern with immune escape.
    Sanyaolu A; Marinkovic A; Prakash S; Haider N; Williams M; Okorie C; Badaru O; Smith S
    World J Virol; 2022 May; 11(3):137-143. PubMed ID: 35665238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: The 2022 World Health Organization (WHO) Priority Recommendations and Response to the Omicron Variant (B.1.1.529) of SARS-CoV-2.
    Parums DV
    Med Sci Monit; 2022 Feb; 28():e936199. PubMed ID: 35102132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.